Albendazole is a broad spectrum anthelmintic, which is highly effective against a wide range of intestinal helminths. Albendazole exhibits larvicidal, ovicidal and vermicidal activity via inhibition of tubulin polymerization.
Albendazole is a broad spectrum anthelmintic, which is highly effective against a wide range of intestinal helminths. Albendazole exhibits larvicidal, ovicidal and vermicidal activity via inhibition of tubulin polymerization. This causes a cascade of metabolic disruption, including energy depletion, which immobilizes and kills the susceptible helminth
Albentel-400 Tablet: Each chewable tablet contains Albendazole USP 400 mg.
Albendazole is effective in the treatment of single or mixed infections caused by pin worm, thread worm, round worms, hook worm, whip worm, Strongyloides stercoralis, animal hookworm larvae causing cutaneous sinensis. It is also indicated for the treatment of Hymenolepsis nana and Taenia spp. (hoook worm) infections, when other susceptible helminths species are present.
Adults of children over 2 years of age: 400 mg as a single dose. In cases of strongyloidiasis or taeniasis, 400 mg as single dose should be given for 3 consecutive days. If the patient is not cured on follow-up after three weeks, a second course of treatment is indicated. Children of 1-2 years: Recommended dose is a single dose of 200 mg. Children under 1 year: Not recommended.
Abentel is contraindicated in persons who are known to be hypersensitive to albendazole, other benzimidazole derivatives, or any component of the tablet.
Cimetidine, praziquantel and dexamethasone have been reported to increase the plasma level of Albendazole active metabolite.
Abdominal pain was the most frequently reported symptom during short term dosing. Diarrhea, nausea, vomiting, dizziness, and/or skin rashes were also reported.
Use in pregnancy (pregnancy category D):Albendazole is contraindicated during pregnancy and for one month prior to conception. In order to avoid administering albendazole during early pregnancy, women of childbearing age (15-45) should initiate treatment during the first week of menstruation or after a negative pregnancy test.
Use in lactation: Adequate human and animal data on use during lactation are not available. Therefore breast-feeding should be discontinued during and for a minimum of 5 days after treatment.
Abentel-400 Tablet: Each box contains 50 tablets
FR
DE